Zhongguancun Medical Equipment Supply and Demand Matchmaking Conference held

Forty innovative products from 30 Zhongguancun enterprises were unveiled at the Zhongguancun Medical Equipment Online Supply and Demand Matchmaking Conference on July 21. Representatives from more than 200 municipal and district hospitals attended the event.

Nine enterprises including Arrays Medical Imaging, WeMed Medical Equipment, and Shukun Network presented products in the field of medical imaging and cardiovascular disease.

One of them, the first domestic high-end SPECT developed by Novel Medical, can reflect various changes in organ function and blood flow indicators through accurate detection of the distribution of radionuclides in the human body, and can conduct functional research of various organs and diagnosis of related diseases.

China's first pre-clinical three-modality animal molecular imaging product, also developed by Novel Medical, can track the metabolic process of drugs in the animal body in vivo, and verify the pathological characteristics and toxicity of drugs, which greatly improves the efficiency of R&D in new drugs.

Med-zenith also presented two products: the first domestic radiofrequency ablation system suitable for the treatment of atrial fibrillation and a pulmonary artery stent for the treatment of pulmonary artery stenosis. The pulmonary artery stent, the only product in the world specially designed for patients with pulmonary artery stenosis, can be used in the treatment of congenital heart diseases at various stages.

Surgical equipment, treatment equipment, inspection and testing equipment and ventilators were also presented at the event. For example, the first domestic neurosurgery robot independently developed by Sinovation can realize non-contact visual positioning, intracranial vascular reconstruction, intelligent obstacle avoidance and force sensing, and the respiratory neuromuscular stimulator developed by Yaguo Technology can be used to treat chronic obstructive pulmonary disease (COPD) and ICU acquired weakness.

In the first half of the year, 75 Class III medical devices were approved for listing in Beijing, and BioChain's RNF180/Septin9 gene methylation detection kit that is used in the early screening of gastric cancer passed the national special examination for innovative medical devices.

Up to now, 22 national innovative medical devices have been approved for listing in Beijing, accounting for about one-third of those submitted. Seven biopharmaceutical enterprises have been listed this year. TINAVI Medical Technology, SinoCellTech, and Eyebright have been listed on the science and technology innovation board, and two biological enterprises are expected to be listed.